6271 related articles for article (PubMed ID: 21061759)
1. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone.
Martiniuk F; Damian DL; Thompson JF; Scolyer RA; Tchou-Wong KM; Levis WR
J Drugs Dermatol; 2010 Nov; 9(11):1368-72. PubMed ID: 21061759
[TBL] [Abstract][Full Text] [Related]
2. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma.
Damian DL; Shannon KF; Saw RP; Thompson JF
Australas J Dermatol; 2009 Nov; 50(4):266-71. PubMed ID: 19916970
[TBL] [Abstract][Full Text] [Related]
3. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
Damian DL; Saw RP; Thompson JF
J Surg Oncol; 2014 Mar; 109(4):308-13. PubMed ID: 24522938
[TBL] [Abstract][Full Text] [Related]
4. Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience.
Veverka KK; Jakub JW; Baum CL
Dermatol Surg; 2018 Dec; 44(12):1501-1508. PubMed ID: 29985863
[TBL] [Abstract][Full Text] [Related]
5. Response rates of cutaneous melanoma metastases to diphencyprone: A meta-analysis.
Lôbo MM; Calsavara VF; Ricci BV; Lopes Pinto CA; Bertolli E; Duprat Neto JP
J Am Acad Dermatol; 2020 Dec; 83(6):1812-1813. PubMed ID: 32289400
[No Abstract] [Full Text] [Related]
6. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone.
Damian DL; Thompson JF
J Am Acad Dermatol; 2007 May; 56(5):869-71. PubMed ID: 17276544
[TBL] [Abstract][Full Text] [Related]
7. Sequencing in management of in-transit melanoma metastasis: Diphencyprone versus isolate limb infusion.
Lo MC; Garioch J; Moncrieff MD
J Plast Reconstr Aesthet Surg; 2020 Jul; 73(7):1263-1267. PubMed ID: 32245735
[TBL] [Abstract][Full Text] [Related]
8. Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine.
Harland CC; Saihan EM
Lancet; 1989 Aug; 2(8660):445. PubMed ID: 2569622
[No Abstract] [Full Text] [Related]
9. Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
Yeung C; Petrella TM; Wright FC; Abadir W; Look Hong NJ
Expert Rev Clin Immunol; 2017 Apr; 13(4):383-388. PubMed ID: 28121191
[TBL] [Abstract][Full Text] [Related]
10. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg.
Damian DL; Thompson JF
Am J Clin Dermatol; 2011 Dec; 12(6):403-4. PubMed ID: 21967115
[No Abstract] [Full Text] [Related]
11. Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience.
Gibbons IL; Sonagli M; Bertolli E; Macedo MP; Pinto CAL; Duprat Neto JP
An Bras Dermatol; 2018 Mar; 93(2):299-301. PubMed ID: 29723355
[TBL] [Abstract][Full Text] [Related]
12. Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases - results of a prospective, non-randomized, single-centre study.
Read T; Webber S; Tan J; Wagels M; Schaider H; Soyer HP; Smithers BM
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2030-2037. PubMed ID: 28626861
[TBL] [Abstract][Full Text] [Related]
13. Lesional therapies for in-transit melanoma.
Nadler A; Look Hong NJ; Alavi N; Abadir W; Wright FC
J Surg Oncol; 2020 Nov; 122(6):1050-1056. PubMed ID: 32668038
[TBL] [Abstract][Full Text] [Related]
14. Primary mucosal melanoma arising from the eustachian tube with CTLA-4, IL-17A, IL-17C, and IL-17E upregulation.
Wei C; Sirikanjanapong S; Lieberman S; Delacure M; Martiniuk F; Levis W; Wang BY
Ear Nose Throat J; 2013 Jan; 92(1):36-40. PubMed ID: 23354891
[TBL] [Abstract][Full Text] [Related]
15. Complete remission of extensive cutaneous metastatic melanoma on the scalp under topical mono-immunotherapy with diphenylcyclopropenone.
Hinz T; Ehler LK; Bieber T; Schmid-Wendtner MH
Eur J Dermatol; 2013; 23(4):532-3. PubMed ID: 24002471
[No Abstract] [Full Text] [Related]
16. [Treatment of metastatic melanoma with CTLA4 antibodies].
Hafner C
Hautarzt; 2010 Sep; 61(9):808-10. PubMed ID: 20721523
[No Abstract] [Full Text] [Related]
17. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
[No Abstract] [Full Text] [Related]
18. Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin; the 5-year Norwich experience.
Moncrieff M; Fadhil M; Garioch J
Br J Dermatol; 2016 May; 174(5):1141-2. PubMed ID: 26598951
[No Abstract] [Full Text] [Related]
19. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
Green DS; Dalgleish AG; Belonwu N; Fischer MD; Bodman-Smith MD
Br J Dermatol; 2008 Sep; 159(3):606-14. PubMed ID: 18616776
[TBL] [Abstract][Full Text] [Related]
20. PLZF regulates CCR6 and is critical for the acquisition and maintenance of the Th17 phenotype in human cells.
Singh SP; Zhang HH; Tsang H; Gardina PJ; Myers TG; Nagarajan V; Lee CH; Farber JM
J Immunol; 2015 May; 194(9):4350-61. PubMed ID: 25833398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]